Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Asher Chanan-Khan, MD
Conference Coverage
Benefits of BCL-2 Targeting Treatment for Patients With Chronic Lymphocytic Leukemia
01/29/2024

Featuring Asher Chanan-Khan, MD

Featuring Asher Chanan-Khan, MD ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL). 
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL). 
At the 2023 Lymphoma, Leukemia &...
01/29/2024
Lymphoma, Leukemia & Myeloma Network
Asher Chanan-Khan, MD
Conference Coverage
Benefits of BCL-2 Targeting Treatment for Patients With Chronic Lymphocytic Leukemia
01/29/2024

Featuring Asher Chanan-Khan, MD

Featuring Asher Chanan-Khan, MD ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL). 
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL). 
At the 2023 Lymphoma, Leukemia &...
01/29/2024
Lymphoma, Leukemia & Myeloma Network
Javier Pinilla-Ibarz, MD, PhD
Conference Coverage
Utilizing BTK Inhibitors to Treat Patients With Chronic Lymphocytic Leukemia
01/29/2024

Featuring Javier Pinilla-Ibarz, MD, PhD

Featuring Javier Pinilla-Ibarz, MD, P...
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.
During the 2023 Lymphoma,...
01/29/2024
Lymphoma, Leukemia & Myeloma Network
Javier Pinilla-Ibarz, MD, PhD
Conference Coverage
Utilizing BTK Inhibitors to Treat Patients With Chronic Lymphocytic Leukemia
01/29/2024

Featuring Javier Pinilla-Ibarz, MD, PhD

Featuring Javier Pinilla-Ibarz, MD, P...
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.
During the 2023 Lymphoma,...
01/29/2024
Lymphoma, Leukemia & Myeloma Network
Adriana Rossi, MD, Mount Sinai
Conference Coverage
CAR-T Cell Therapy vs Stem Cell Transplant for the Treatment of Patients With Multiple Myeloma
01/24/2024

Featuring Adriana Rossi, MD

Featuring Adriana Rossi, MD
During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.
During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.
During a debate at the 2023...
01/24/2024
Lymphoma, Leukemia & Myeloma Network
Adriana Rossi, MD, Mount Sinai
Conference Coverage
CAR-T Cell Therapy vs Stem Cell Transplant for the Treatment of Patients With Multiple Myeloma
01/24/2024

Featuring Adriana Rossi, MD

Featuring Adriana Rossi, MD
During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.
During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.
During a debate at the 2023...
01/24/2024
Lymphoma, Leukemia & Myeloma Network
Dan Vogl, MD, University of Pennsylvania
Conference Coverage
Evaluating Bispecific T-Cell Engagers for the Treatment of Patients With Multiple Myeloma
01/23/2024

Featuring Dan Vogl, MD

Featuring Dan Vogl, MD
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma,...
01/23/2024
Lymphoma, Leukemia & Myeloma Network
Dan Vogl, MD, University of Pennsylvania
Conference Coverage
Evaluating Bispecific T-Cell Engagers for the Treatment of Patients With Multiple Myeloma
01/23/2024

Featuring Dan Vogl, MD

Featuring Dan Vogl, MD
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma,...
01/23/2024
Lymphoma, Leukemia & Myeloma Network
Faith E. Davies, MD, Perlmutter Cancer Center
Conference Coverage
Choosing a Treatment Strategy for Patients With Early Relapsed Multiple Myeloma
01/22/2024

Featuring Faith E. Davies, MD

Featuring Faith E. Davies, MD
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.
During the 2023 Lymphoma,...
01/22/2024
Lymphoma, Leukemia & Myeloma Network
Faith E. Davies, MD, Perlmutter Cancer Center
Conference Coverage
Choosing a Treatment Strategy for Patients With Early Relapsed Multiple Myeloma
01/22/2024

Featuring Faith E. Davies, MD

Featuring Faith E. Davies, MD
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.
During the 2023 Lymphoma,...
01/22/2024
Lymphoma, Leukemia & Myeloma Network

Advertisement

Advertisement

About

For nearly 2 decades, the Lymphoma, Leukemia & Myeloma Congress (formerly the Lymphoma & Myeloma Congress) has been recognized around the world as the most respected forum for industry-leading hematologic research.

It’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use